The pharmacokinetic profile of fesoterodine: similarities and differences to tolterodine.

@article{Simon2009ThePP,
  title={The pharmacokinetic profile of fesoterodine: similarities and differences to tolterodine.},
  author={Hans-Uwe Simon and Bimal Malhotra},
  journal={Swiss medical weekly},
  year={2009},
  volume={139 9-10},
  pages={146-51}
}
BACKGROUND Fesoterodine is a new antimuscarinic agent developed for the treatment of overactive bladder. Fesoterodine itself is inactive and is rapidly and extensively converted by ubiquitous esterases to its principal active moiety, 5-hydroxymethyl tolterodine (5-HMT). 5-HMT is formed via biotransformation of both fesoterodine and tolterodine, albeit by different metabolising enzymes, viz. esterases and CYP2D6 respectively. Tolterodine is a potent muscarinic receptor antagonist and has been… CONTINUE READING